The dosing presented on the page without maximum dose qualification and the important advice listed in the SPC as to when medical assessment was needed, was alleged to be in breach of the Code.Ģ The complainant stated that the first part of the advertisement on practice nurse website (GB-30263 August 2021) claimed that ‘Trixeo offered triple protection for moderate to severe COPD patients from exacerbations, hospitalisations and symptoms’.
The complainant stated that whether this was dosing for Symbicort in COPD (chronic obstructive pulmonary disease) or asthma was also not presented on the dosing information. The way the dosing was written was incorrect as when required usage seemed infinite with no maximum dosage in the way it was presented on the page, which could cause overdosing.
The complainant was concerned that no maximum dosage was stated as indicated in the summary of product characteristics (SPC) for Symbicort 100/3 pMDI device.
LAMA LABA VS SYMBICORT CODE
The complainant stated that he/she had concerns over stretching the boundaries of the Code by AstraZeneca’s promotional content on various webpages.ġ The complainant stated that on the Symbicort turbohaler and pMDI devices webpage ( GB-31536 October 2021) underneath mention of Symbicort pMDI 100/3, dosing was noted as ‘Two inhalations in the morning, two inhalations in the evening and two inhalations as needed’. An anonymous contactable complainant who described themselves as a health professional complained about the promotion of Symbicort turbohaler (budesonide/formoterol), Trixeo (formoterol/budesonide/glycopyrronium), Bevespi (glycopyrronium/formoterol) and Daxas (roflumilast).
0 kommentar(er)
